Exelixis, Inc.

EXEL: NasdaqGS
71Total

Lowest reading is at 42 out of 100. All scores are out of 100.

About The Company

CEO

Dr. Michael M. Morrissey Ph.D.

Market Cap

14.41 Billion USD

Sector

Healthcare

Website

https://www.exelixis.com

Last Update

27/09/2026, 17:21:37

Description

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Read More

Strongest readings

  • ✔Altman-Z score of 14.15 sits above the distress range
  • ✔Financial health is strong (health score 90 out of 100)
  • ✔Debt is low at 0.09 times equity
  • ✔Share count has been falling at 1.04% per year
  • ✔Return on capital employed of 11.65% is above the market average of 10.00%

Weakest readings

  • ✘The current price sits above estimated fair value (margin of safety -78.57%)

Key Figures

StatusMetricValueReadingMarket avg
✔
Price / earnings (TTM)
17.73x
19.60x
✘
Margin of safety (DCF)
-78.57%
17.95%
✘
Revenue growth (5y average)
1.83%
10.97%
✘
Dividend yield (TTM)
0.00%
1.85%
✔
Share count, per year
-1.04%
0.00%
✔Return on capital employed11.65%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

64 / 100

Priced at or below the market on most measures.

StatusMetricValueReadingMarket avg
✔
Price / earnings
17.73x
19.60x
✔Free cashflow yield8.14%
4.70%
✘Price / earnings growth3.59x
1.50x
Price / book7.82x
—
✘
Margin of safety
-78.57%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 12.46 USD is below the current price of 58.16 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: 17.7 USD ✘

Current Price: 58.2 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

42 / 100

Growing more slowly than the market on most measures.

StatusMetricValueReadingMarket avg
✘
Revenue growth
1.83%
10.97%
✘Earnings growth5.41%
14.48%
✔Cashflow growth17.64%
12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✔Revenue growth has improved this year (9.23% against a five year average of 1.83%)
  • ✔Earnings growth has improved this year (53.13% against a five year average of 5.41%)
  • ✔Free cashflow growth has improved this year

Health

90 / 100

Balance sheet covers its obligations.

Measured on Leverage and capital, Funding and liquidity, Earnings quality.

StatusMetricValueReadingThreshold
✔Altman-Z score14.15
3.00
✔Piotroski score7.00
5.00
✔Debt / equity0.09x
0.80x
✔Current ratio3.46x
1.00x
Interest coverageN/A2.50x
✔Free cashflow / debt1.81x
0.15x
✔Debt / capital0.08x
1.00x

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Management

    87 / 100

    Returns on capital are at or above the market.

    StatusMetricValueReadingMarket avg
    ✘Return on equity11.50%
    15.00%
    ✔Return on capital employed11.65%
    10.00%
    Return on assets8.50%
    —
    Free cashflow return on capital14.11%
    —
    ✔Return on capital, 5y change2.38%
    0.00%
    ✔
    Share count, per year
    -1.04%
    0.00%
    ✔Share count, recent-1.21%
    0.00%
    ✔Realized buyback return47.46%
    0.00%
    ✔Goodwill erosion / equity0.00%
    2.00%
    Price volatility, 5 year35.88%
    —

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✔Shares were repurchased while the value score was 64 out of 100

    Analysts

    not enough data
    StatusMetricValueReadingNeutral
    Analyst opinion scoreN/A50

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Financial History

    Annual figures across the full reporting history we hold.

    Market Peers

    EXEL

    SEC Filings

    Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

    See 35+ Years Annual Reports

    Other Information

    Company Name

    Exelixis, Inc.

    Currency

    USD

    Beta

    0.422

    Vol Avg

    2393308

    Ceo

    Dr. Michael M. Morrissey Ph.D.

    Cik

    0000939767

    Cusip

    Exchange

    NasdaqGS

    Full Time Employees

    1077

    Industry

    Biotechnology

    Sector

    Healthcare

    Ipo Date

    Address

    1851 Harbor Bay Parkway

    City

    Alameda

    State

    CA

    Country

    United States

    Zip

    94502

    Phone

    650 837 7000

    Analysis Last Updated

    27/09/2026, 17:21:37

    Financial data compiled from SEC EDGAR filings and Yahoo Finance.

    Noticed an error with something on our site?

    Data, not advice. Do your own diligence.

    We Use Cookies